Mid-Afternoon Market Update: Dow Jumps 300 Points; Krystal Biotech Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.87% to 35,204.42 while the NASDAQ climbed 1.96% to 15,795.08. The S&P also rose, gaining 1.55% to 4,665.67.
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $124
HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $103 to $124.
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
Midway through trading Monday, the Dow traded up 0.30% to 35,005.10 while the NASDAQ climbed 1.39% to 15,707.48. The S&P also rose, gaining 0.97% to 4,639.11.
33 Stocks Moving In Monday’s Mid-Day Session
Gainers
Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB).
Mid-Morning Market Update: Markets Open Higher; Li Auto Sales Top Views
Following the market opening Monday, the Dow traded up 0.22% to 34,977.01 while the NASDAQ climbed 1.53% to 15,727.94. The S&P also rose, gaining 0.92% to 4,637.03.
Krystal Biotech Announces Topline Results From GEM-3 Pivotal Trial of VYJUVEK In Patients With Dystrophic Epidermolysis Bullosa; Co. Reports ‘Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints’
Pivotal GEM-3 trial met its primary endpoint of complete wound healing at six-month timepoints,
and its secondary endpoint of complete wound healing at three-month timepoints
VYJUVEKTM was well tolerated, with
